AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
AN2 Therapeutics (Nasdaq: ANTX), a biopharmaceutical company specializing in novel small molecule therapeutics derived from boron chemistry, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. Eric Easom, the company's Co-Founder, Chairman, President, and CEO, will deliver a corporate overview on Tuesday, September 10 at 9:30am ET.
Investors and interested parties can access a webcast of the presentation through the Investors section of AN2 Therapeutics' website. The company will also provide an archived replay of the presentation, available for at least 30 days following the event. This conference appearance offers an opportunity for AN2 Therapeutics to showcase its progress and strategy in developing innovative therapeutics based on its proprietary boron chemistry platform.
AN2 Therapeutics (Nasdaq: ANTX), un'azienda biofarmaceutica specializzata in nuove terapie a piccole molecole derivate dalla chimica del boro, ha annunciato la sua partecipazione alla 26ª Conferenza Globale Annuale sugli Investimenti H.C. Wainwright. Eric Easom, co-fondatore, presidente e CEO dell'azienda, offrirà una panoramica aziendale martedì 10 settembre alle 9:30 ET.
Investitori e parti interessate possono accedere a un webcast della presentazione attraverso la sezione Investitori del sito web di AN2 Therapeutics. L'azienda fornirà anche una registrazione archiviata della presentazione, disponibile per almeno 30 giorni dopo l'evento. Questa partecipazione alla conferenza offre un'opportunità per AN2 Therapeutics di mettere in mostra i propri progressi e la strategia nello sviluppo di terapie innovative basate sulla propria piattaforma di chimica del boro.
AN2 Therapeutics (Nasdaq: ANTX), una empresa biofarmacéutica especializada en nuevas terapias de pequeñas moléculas derivadas de la química del boro, ha anunciado su participación en la 26ª Conferencia Anual Global de Inversiones H.C. Wainwright. Eric Easom, cofundador, presidente y CEO de la empresa, realizará una visión general de la empresa el martes 10 de septiembre a las 9:30 a.m. ET.
Los inversores y partes interesadas pueden acceder a un webcast de la presentación a través de la sección de Inversores del sitio web de AN2 Therapeutics. La empresa también proporcionará una repetición archivada de la presentación, disponible por al menos 30 días después del evento. Esta aparición en la conferencia ofrece a AN2 Therapeutics la oportunidad de mostrar su progreso y estrategia en el desarrollo de terapias innovadoras basadas en su plataforma propietaria de química del boro.
AN2 Therapeutics (Nasdaq: ANTX)는 붕소 화학에서 유래한 신규 소분자 치료제를 전문으로 하는 생명공학 회사로, H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 참여한다고 발표했습니다. 회사의 공동 창립자이자 회장, 사장 겸 CEO인 Eric Easom이 2023년 9월 10일 화요일 오전 9:30 ET에 기업 개요를 발표할 예정입니다.
투자자와 이해관계자는 AN2 Therapeutics 웹사이트의 투자자 섹션을 통해 발표의 웨비나에 접근할 수 있습니다. 회사는 또한 행사 후 최소 30일 동안 제공되는 발표의 아카이브 재생을 제공합니다. 이번 컨퍼런스 참가를 통해 AN2 Therapeutics는 자사의 독점 붕소 화학 플랫폼을 기반으로 한 혁신적인 치료제 개발에서의 진행 상황과 전략을 선보일 수 있는 기회를 제공합니다.
AN2 Therapeutics (Nasdaq: ANTX), une entreprise biopharmaceutique spécialisée dans les nouvelles thérapies à petites molécules dérivées de la chimie du bore, a annoncé sa participation à la 26ème Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright. Eric Easom, co-fondateur, président et PDG de l'entreprise, présentera un aperçu de l'entreprise mardi 10 septembre à 9h30 ET.
Les investisseurs et les parties intéressées peuvent accéder à un webcast de la présentation via la section Investisseurs du site web d'AN2 Therapeutics. L'entreprise fournira également une rediffusion archivée de la présentation, disponible pendant au moins 30 jours après l'événement. Cette apparition à la conférence offre à AN2 Therapeutics l'occasion de mettre en valeur ses progrès et sa stratégie de développement de thérapies innovantes basées sur sa plateforme de chimie du bore exclusive.
AN2 Therapeutics (Nasdaq: ANTX), ein biopharmazeutisches Unternehmen, das sich auf neue kleine Molekültherapeutika aus der Borchemie spezialisiert hat, hat seine Teilnahme an der 26. jährlichen globalen Investitionskonferenz von H.C. Wainwright bekannt gegeben. Eric Easom, Mitgründer, Vorsitzender, Präsident und CEO des Unternehmens, wird am Dienstag, den 10. September um 9:30 Uhr ET einen Unternehmensüberblick präsentieren.
Investoren und Interessierte können über den Investor-Bereich der Website von AN2 Therapeutics auf einen Webcast der Präsentation zugreifen. Das Unternehmen wird auch eine archivierte Wiederholung der Präsentation bereitstellen, die mindestens 30 Tage nach der Veranstaltung verfügbar ist. Diese Teilnahme an der Konferenz bietet AN2 Therapeutics die Möglichkeit, Fortschritte und Strategien bei der Entwicklung innovativer Therapeutika auf Grundlage seiner proprietären Borchemie-Plattform zu präsentieren.
- None.
- None.
Details of the event is as follows:
H.C. Wainwright 26th Annual Global Investment Conference
- Eric Easom, Co-Founder, Chairman, President and CEO will provide a corporate overview on Tuesday, September 10 at 9:30am ET
A webcast of the presentation can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation.
About AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. AN2 has a pipeline of boron-based compounds in development for Chagas disease, nontuberculous mycobacteria (NTM), and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. For more information, please visit our website at www.an2therapeutics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828371113/en/
COMPANY CONTACT:
Lucy O. Day
Chief Financial Officer
l.day@an2therapeutics.com
INVESTOR AND MEDIA CONTACT:
Anne Bowdidge
ir@an2therapeutics.com
Source: AN2 Therapeutics, Inc.
FAQ
When is AN2 Therapeutics (ANTX) presenting at the H.C. Wainwright Global Investment Conference?
Who will be presenting for AN2 Therapeutics (ANTX) at the investment conference?
How can investors access AN2 Therapeutics' (ANTX) presentation at the H.C. Wainwright conference?
What is the focus of AN2 Therapeutics' (ANTX) research and development?
